Valuation: Cipher Pharmaceuticals Inc.

Market Cap 423M 301M 263M 243M 223M 29.01B 430M 2.9B 1.14B 14.16B 1.13B 1.11B 48.9B P/E 2026 *
13.6x
P/E 2027 * 12.1x
Enterprise Value 423M 301M 263M 243M 223M 29.01B 430M 2.9B 1.14B 14.16B 1.13B 1.11B 48.9B EV / Sales 2026 *
5.78x
EV / Sales 2027 * 5x
Free-Float
57.64%
Yield 2026 *
-
Yield 2027 * -
1 day-1.50%
1 week-3.19%
Current month-1.68%
1 month+1.11%
3 months-11.60%
6 months+6.43%
Current year+8.83%
1 week 16.31
Extreme 16.31
17.22
1 month 15.93
Extreme 15.93
17.8
Current year 14.2
Extreme 14.2
20.56
1 year 11.98
Extreme 11.98
20.56
3 years 3.35
Extreme 3.35
20.56
5 years 1.43
Extreme 1.43
20.56
10 years 0.38
Extreme 0.38
20.56
Manager TitleAgeSince
Chief Executive Officer - 2019-07-28
Director of Finance/CFO - 2024-08-09
Director of Finance/CFO - 2022-08-14
Director TitleAgeSince
Chairman - 2019-06-11
Director/Board Member 78 2023-06-20
Director/Board Member - 2023-06-20
Date Insider Type Main position Quantity % Market Cap.
6/24/26 Option

Chief Executive Officer

-2,500 0.0098%
6/24/26 Option

Director

-1,149 0.0045%
6/24/26 Option

Chief Executive Officer

2,500 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
-1.50%-3.19%+28.25%+361.69% 301M
+1.08%-3.93%+48.03%+161.48% 1,031B
+1.19%-3.52%+51.70%+57.14% 595B
+4.21%+1.79%+33.48%+88.67% 431B
+0.42%-0.99%+30.04%+22.27% 326B
+1.03%-2.10%+28.32%+45.08% 277B
+0.49%-11.32%+20.31%+22.32% 263B
+1.59%+3.91%-22.47%-36.84% 224B
+3.70%+2.19%+24.27%+63.09% 193B
+3.49%+1.08%+24.08%+75.92% 164B
Average +1.33%-3.63%+26.60%+86.08% 350.46B
Weighted average by Cap. +1.56%-4.31%+34.62%+80.14%

Financials

2026 *2027 *
Net sales 73.13M 52.09M 45.53M 42.11M 38.64M 5.02B 74.4M 502M 197M 2.45B 196M 191M 8.46B 84.52M 60.2M 52.63M 48.67M 44.66M 5.8B 85.99M 580M 228M 2.83B 226M 221M 9.78B
Net income 30.44M 21.68M 18.95M 17.53M 16.08M 2.09B 30.97M 209M 82.12M 1.02B 81.43M 79.64M 3.52B 36.1M 25.71M 22.47M 20.78M 19.07M 2.48B 36.72M 248M 97.37M 1.21B 96.55M 94.43M 4.18B
Net Debt - -
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
26-07-16 $16.39 -1.50% 18,583
26-07-15 $16.64 -0.72% 6,105
26-07-14 $16.76 -0.83% 13,529
26-07-13 $16.90 -1.34% 17,900
26-07-10 $17.13 +1.18% 12,338
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
16.64CAD
Average target price
20.64CAD
Spread / Average Target
+24.02%

Quarterly revenue - Rate of surprise